Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Kaplan

Psychiatry Exeter, NH Doctor of Osteopathy

NPI 1205061355 CMS profile 1304194

24 Front St Ste 100, Exeter, NH 03833

Open in the dashboard

General payments

$3,226

105 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Kaplan of Exeter, NH is reported in the CMS Open Payments database as having received $3,226 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $214 2
2024 General $244 2
2023 General $237 2
2022 General $138 8
2021 General $538 23
2020 General $221 9
2019 General $1,634 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Kaplan
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Andrew Kaplan were reported at $214. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Andrew Kaplan Psychiatry median Middle half National median
2019 $1,634 $184 $59–$605 $163
2020 $221 $119 $36–$372 $114
2021 $538 $143 $43–$576 $132
2022 $138 $153 $50–$590 $149
2023 $237 $170 $56–$651 $160
2024 $244 $179 $57–$673 $164
2025 $214 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $535 22 payments
  2. Axsome Therapeutics, Inc. $492 4 payments
  3. Ironshore Pharmaceuticals Inc. $350 3 payments
  4. Otsuka America Pharmaceutical, Inc. $320 12 payments
  5. Allergan Inc. $287 18 payments
  6. Teva Pharmaceuticals USA, Inc. $240 4 payments
  7. Janssen Pharmaceuticals, Inc $222 14 payments
  8. Supernus Pharmaceuticals, Inc. $222 13 payments
  9. ITI, Inc. $217 2 payments
  10. AbbVie, Inc. $169 4 payments
  11. Other $173 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,226 105 payments
Products named General payments · program years 2019–2025
  1. LATUDA $535 22 payments
  2. Auvelity $492 4 payments
  3. Jornay PM 20mg capsules (Bottle of 100) $336 2 payments
  4. REXULTI $320 12 payments
  5. VRAYLAR Neuroscience $287 18 payments
  6. AUSTEDO $240 4 payments
  7. QELBREE $222 13 payments
  8. INVEGA SUSTENNA $200 13 payments
  9. INVEGA TRINZA $187 12 payments
  10. VRAYLAR Neuroscience $169 4 payments
  11. Other $688 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record